Back to search results

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Locally Advanced Triple Negative Breast Cancer · TNBC - Triple-Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mount Sinai Health System, New York, New York, United States

    Contact: Study coordinator (Katherine Vandris) · Katherine.Vandris@mssm.edu
    Contact: Principal Investigator (Rima Patel)
Study leads

  • Rima Patel, MD

    Principal Investigator

    Icahn School of Medicine at Mount Sinai

  • Joseph Sparano, MD

    Principal Investigator

    Icahn School of Medicine at Mount Sinai

View source on ClinicalTrials.gov(opens in a new tab)